Victoria L. Peek

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ling Liu, Wei Zeng, Mark A. Wortinger et al. · Clinical Cancer Research · 2014 · 109 citations

Medicine, Cancer Biology, Oncology +15

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Sheng-Bin Peng, Victoria L. Peek, Yan Zhai et al. · Molecular Cancer Research · 2005 · 107 citations

Life Sciences, Cell Biology, Molecular Biology +13

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Wenjuan Wu, Bi Chen, Kelly M. Credille et al. · Clinical Cancer Research · 2013 · 68 citations · Full text

Medicine, Oncology, Pharmacology +12

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Bruce W. Konicek, Andrew Capen, Kelly M. Credille et al. · Oncotarget · 2018 · 50 citations · Full text

Medicine, Oncology, Pharmacology +17